New onset atrial fibrillation after patent foramen ovale closure

Catheterization and Cardiovascular Interventions

Volumn 74, Issue 6, 2009, Pages 889-895

  Staubach, Stephan ^a   Steinberg, Daniel H ^b   Zimmermann, Wibke ^a   Wawra, Nikolaus ^a   Wilson, Neil ^a   Wunderlich, Nina ^a   Sievert, Horst ^a  

^a CARDIOVASCULAR CENTER FRANKFURT   (Germany)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Atrial arrhythmia; Congenital heart disease; Different devices; Patent foramen ovale; Transcatheter closure

Indexed keywords

ANTIARRHYTHMIC AGENT; WARFARIN;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; ARTIFICIAL EMBOLISM; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; DECOMPRESSION SICKNESS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; IMPLANT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; RISK ASSESSMENT; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CHRONIC DISEASE; ELECTROCARDIOGRAPHY; FEMALE; FORAMEN OVALE, PATENT; HEART CATHETERIZATION; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEPTAL OCCLUDER DEVICE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73249118541     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22172     Document Type: Article

References (33)

1. Beitzke A, Schuchlenz H, Gamillscheg A, et al. Catheter closure of the persistent foramen ovale: Mid-term results in 162 patients. J Interv Cardiol 2001;14:223-229.
2. Sievert H, Horvath K, Zadan E, et al. Patent foramen ovale closure in patients with transient ischemia attack/stroke. J Interv Cardiol 2001;14:261-266.
3. Slavin L, Tobis JM, Rangarajan K, et al. Five-year experience with percutaneous closure of patent foramen ovale. Am J Cardiol 2007;99:1316-1320.
4. Martin F, Sanchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002;106:1121-1126.
5. Braun M, Gliech V, Boscheri A, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J 2004;25: 361-362.
6. Homma S, Sacco RL, Di Tullio MR, et al. PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: Patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-2631.
7. Bruch L, Parsi A, Grad MO, et al. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: Single-center experience. Circulation 2002;105: 2845-2848.
8. Guérin P, Lambert V, Godart F, et al. Transcatheter closure of patent foramen ovale in patients with platypnea-orthodeoxia: Results of a multicentric French registry. Cardiovasc Intervent Radiol 2005;28:164-168.
9. Buscheck F, Sievert H, Kleber F, et al. Patent foramen ovale using the Premere device: The results of the CLOSEUP trial. J Interv Cardiol 2006;19:328-333.
10. Kiblawi FM, Sommer RJ, Levchuck SG. Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc Interv 2006;68:136-142 (discussion 143-144).
11. Chatterjee T, Petzsch M, Ince H, et al. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. J Interv Cardiol 2005;18:173-179.
12. Bijl JM, Ruygrok PN, Hornung TS, et al. Percutaneous closure of patent foramen ovale. Intern Med J 2005;35:706-710.
13. Bailey CE, Allaqaband S, Bajwa TK. Current management of patients with patent foramen ovale and cryptogenic stroke: Our experience and review of the literature. WMJ 2004;103:32-36 (review).
14. Alameddine F, Block PC. Transcatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: Acute results from the forecast registry. Catheter Cardiovasc Interv 2004;62:512.
15. Onorato E, Melzi G, Casilli F, et al. Patent foramen ovale with paradoxical embolism: Mid-term results of transcatheter closure in 256 patients. J Interv Cardiol 2003;16:43-50.
16. Schwerzmann M, Windecker S, Wahl A, et al. Percutaneous closure of patent foramen ovale: Impact of device design on safety and efficacy. Heart 2004;90:186-190.
17. Carminati M, Giusti S, Hausdorf G, et al. A European multicentric experience using the CardioSEal and Starflex double umbrella devices to close interatrial communications holes within the oval fossa. Cardiol Young 2000;10:519-526.
18. Alaeddini J, Wood MA, Lee BP, et al. Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale. J Invasive Cardiol 2006;18:365-368.
19. Burow A, Schwerzmann M, Wallmann D, et al. Atrial fibrillation following device closure of patent foramen ovale. Cardiology 2008;111:47-50.
20. European Heart Rhythm Association; Heart Rhythm Society, Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906.
21. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
22. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-2375.
23. Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm 2006;3:1445-1452.
24. Oral H, Veerareddy S, Good E, et al. Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2004;15:925-926.
25. Camm AJ, Evans KE, Ward DE, et al. The rhythm of the heart in active elderly subjects. Am Heart J 1980;99:598-603.
26. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96: 2455-2461.
27. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-241.
28. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a populationbased cohort. The Framingham Heart Study. JAMA 1994;271:840-844.
29. Israel CW, Gronefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. J Am Coll Cardiol 2004;42:47-52.
30. Page RL, Tilsch TW, Connolly SJ, et al. Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or "Silent" atrial fibrillation. Frequency in untreated patients and patients receiving azimilide. Circulation 2003;107: 1141-1145.
31. Piorkowski C, Kottkamp H, Tanner H, et al. Value of different follow up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol 2005;16:1286-1292.
32. Defaye P, Dournaux F, Mouton E. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: The AIDA Study. The AIDA multicenter study group. Automatic interpretation for diagnosis assistance. Pacing Clin Electrophysiol 1998;21:250-255.
33. Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: A transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group. Am Heart J 1992;24:381-386.